Sou Hu Cai Jing·2025-12-30 12:13Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chunli Medical (688236) as of December 30, 2025, showing a stock price increase and significant revenue growth [1][2]. - Chunli Medical reported a main revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [2]. - The net profit attributable to shareholders for the same period was 192 million yuan, reflecting a substantial year-on-year increase of 213.21% [2]. - The company achieved a single-quarter main revenue of 268 million yuan in Q3 2025, which is a remarkable year-on-year increase of 109.51% [2]. - The net profit attributable to shareholders for Q3 2025 was 77.06 million yuan, showing a significant year-on-year increase of 531.12% [2]. - Chunli Medical's gross profit margin stands at 67.27%, indicating strong profitability in its operations [2]. Group 2 - The stock's trading activity on December 30, 2025, showed a net outflow of 846,000 yuan from main funds, accounting for 1.92% of the total trading volume [1]. - Retail investors contributed a net inflow of 868,800 yuan, representing 1.98% of the total trading volume on the same day [1]. - Over the past 90 days, 9 institutions have provided ratings for the stock, with 8 recommending a buy and 1 recommending an increase in holdings [2]. - The average target price set by institutions for Chunli Medical over the past 90 days is 3.18 billion yuan [2].